Core Insights - The biotech industry is showing resilience, particularly due to investment in APAC markets and shifts in R&D priorities, with China emerging as a significant player [2][3] - A strong majority of biotech leaders (92%) are optimistic about reaching their next investment milestones, and 75% plan to increase R&D spending in the next two years [3] - Funding challenges persist, with 41% of organizations actively seeking additional R&D funding, a 27% increase since 2023 [3] Global Biotech Trends - The global biotech survey included 163 respondents and indicates that cell therapy has become the most prominent modality, comprising 40% of pipelines, followed by antibody drug conjugates (ADCs) at 31% [5] - Neurology (44%), cardiovascular (39%), and immune disorders (32%) are now the leading therapeutic focus areas, surpassing oncology [5] - The complexity of drug development is the biggest operational risk, with 73% of respondents ranking it among their top five concerns [6] Digital Transformation - Biotech companies are increasingly adopting digital technologies, with 76% of respondents believing that AI and other technologies will significantly accelerate R&D processes in the next two years [7] - AI-enabled asset selection in drug discovery is seen as a key factor to accelerate drug development, with 41% of respondents highlighting its potential, up from 26% in 2023 [7] Chinese Biotech Market - A separate survey of 100 China-based biotechs revealed that they face similar challenges as their global counterparts, particularly in funding and drug development complexity [8] - Cardiovascular and oncology remain the primary therapeutic focus areas in China, contrasting with the global trend towards neurology [8] - Chinese respondents express less concern about geopolitical issues and show greater confidence in investment and product success [8]